Current Report Filing (8-k)
May 03 2023 - 4:11PM
Edgar (US Regulatory)
0001757499
false
0001757499
2023-05-01
2023-05-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 1, 2023
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41488 |
|
82-5089826
|
(State
or other jurisdiction of
Incorporation) |
|
(Commission
File Number.) |
|
(IRS
Employer
Identification
No.) |
One
Research Court, Suite 450
Rockville,
Maryland 20850
(Address
Of Principal Executive Offices) (Zip Code)
240-430-4212
Registrant’s
telephone Number, including Area Code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock $0.00001 per share |
|
SHPH |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
May 1, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”),
in accordance with a recommendation previously made by the compensation committee of the Company’s board of directors (the “Board”),
awarded a $112,000 annual bonus for fiscal year 2022 (the “Bonus”) to its Chief Executive Officer, Dr. Anatoly Dritschilo,
to reflect the Company’s achievement of certain operational and financial results as set forth in Dr. Dritschilo’s employment
agreement with the Company (the “Employment Agreement”). Under the terms of the Employment Agreement, as previously disclosed,
Dr. Dritschilo was eligible for a bonus, which bonus would be determined at the sole discretion of the Board based on the Company’s
overall performance and Dr. Dritschilo’s performance of his duties under the Employment Agreement.
The
foregoing summary of the terms of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference
to the Employment Agreement, which was filed as Exhibit 10.12 to the Registration Statement on Form S-1 (File No. 333-265429) filed on
June 3, 2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
May 3, 2023 |
|
|
|
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC. |
|
|
|
|
By: |
/s/
Anatoly Dritschilo |
|
Name:
|
Anatoly
Dritschilo |
|
Title: |
Chief
Executive Officer |
|
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Jul 2023 to Jul 2024